Neurological research · 2026
Evaluation of MRI asymptomatic gadolinium-enhancing lesions conversion to persistent black hole with high‑dose methylprednisolone pulse therapy in relapsing remitting multiple sclerosis patients: a randomized trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baghbanian Seyed Mohammad, Bakhshi Atieh, Yazdani Charati Jamshid, Alaee Abdorrasul, Hoseinimayvan Nazanin
Аннотация
BACKGROUND: Chronic black holes (CBHs) on T1-weighted MRI signify irreversible axonal damage in multiple sclerosis (MS).
OBJECTIVES: This research evaluated the potential of intravenous methylprednisolone (IVMP) pulse therapy to prevent asymptomatic contrast-enhancing lesions (CELs) from progressing to chronic black hole (CBHs).
METHODS: In a double‑blind controlled randomized trial during the study period of 2019-2021, 102 people with relapsing-remitting MS with at least one symptom-less contrast-enhancing lesion were randomized into two groups to receive an infusion of methylprednisolone (n = 50) or placebo (n = 52). Repeat MRI imaging was performed 6 months later.
RESULTS: Among 161 CELs, 32 (19.9%) converted to CBHs. Conversion rates were similar between IVMP (18.8%) and placebo (21.0%) (OR = 0.88, 95% CI = 0.38-2.04; p = 0.83). EDSS progression did not differ among groups (p = 0.62). CBH distribution across lesion locations showed no significant differences.
CONCLUSIONS: Intravenous methylprednisolone pulse therapy administered for asymptomatic gadolinium-enhancing lesions was not associated with a statistically significant reduction in the formation of chronic T1 black holes over a 6-month follow-up period.
OBJECTIVES: This research evaluated the potential of intravenous methylprednisolone (IVMP) pulse therapy to prevent asymptomatic contrast-enhancing lesions (CELs) from progressing to chronic black hole (CBHs).
METHODS: In a double‑blind controlled randomized trial during the study period of 2019-2021, 102 people with relapsing-remitting MS with at least one symptom-less contrast-enhancing lesion were randomized into two groups to receive an infusion of methylprednisolone (n = 50) or placebo (n = 52). Repeat MRI imaging was performed 6 months later.
RESULTS: Among 161 CELs, 32 (19.9%) converted to CBHs. Conversion rates were similar between IVMP (18.8%) and placebo (21.0%) (OR = 0.88, 95% CI = 0.38-2.04; p = 0.83). EDSS progression did not differ among groups (p = 0.62). CBH distribution across lesion locations showed no significant differences.
CONCLUSIONS: Intravenous methylprednisolone pulse therapy administered for asymptomatic gadolinium-enhancing lesions was not associated with a statistically significant reduction in the formation of chronic T1 black holes over a 6-month follow-up period.